Literature DB >> 29523321

Utility of the T-SPOT®.TB test's borderline category to increase test resolution for results around the cut-off point.

Karen Rego1, Kristen Pereira1, James MacDougall2, William Cruikshank3.   

Abstract

BACKGROUND: Accurate identification of individuals with TB infection, is required to achieve the WHO's End TB Strategy goals. While there is general acceptance that the T-SPOT.TB test borderline category provides an opportunity to increase test resolution of results around the test cut-off point, this has not been investigated.
METHODS: 645,947 tests were analyzed to determine frequency of borderline results, effect of age and time between tests and associations between subjects' clinical risk factors and retest results.
RESULTS: 645,947 tests produced 93.5% negatives, 4% positives, 0.6% invalids, and 1.8% borderlines. Within the borderline results, 5044 were repeated, with 59.2%, 20.0% and 20.2% resolving to negative, positive and borderline, respectively. Age of subject did not affect retest results; however, time between tests indicated that retest resolution occurred with greatest frequency after 90 days. TB risk factors were provided for 2640 subjects and 17% of low risk subjects with a high initial borderline resolved to negative while 27.6% of subjects with high risk and an initial low borderline resolved to positive, suggesting that these subjects could have been inappropriately classified if using a single cut-off point test with no borderline category.
CONCLUSION: This study demonstrates the utility of the T-SPOT.TB test's borderline category to increase test resolution around the test cut-off point.
Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Borderline result; IGRA; Invalid; Pediatric; T-Cell Xtend; T-SPOT; TB infection

Mesh:

Substances:

Year:  2017        PMID: 29523321     DOI: 10.1016/j.tube.2017.12.005

Source DB:  PubMed          Journal:  Tuberculosis (Edinb)        ISSN: 1472-9792            Impact factor:   3.131


  4 in total

Review 1.  Interferon-gamma release assays in tuberculous uveitis: a comprehensive review.

Authors:  Usanee Tungsattayathitthan; Sutasinee Boonsopon; Nattaporn Tesavibul; Tararaj Dharakul; Pitipol Choopong
Journal:  Int J Ophthalmol       Date:  2022-09-18       Impact factor: 1.645

2.  Human T-cell leukemia virus type 1 may invalidate T-SPOT.TB assay results in rheumatoid arthritis patients: A retrospective case-control observational study.

Authors:  Kunihiko Umekita; Yayoi Hashiba; Kosho Iwao; Chihiro Iwao; Masatoshi Kimura; Yumi Kariya; Kazuyoshi Kubo; Shunichi Miyauchi; Risa Kudou; Yuki Rikitake; Katoko Takajo; Takeshi Kawaguchi; Motohiro Matsuda; Ichiro Takajo; Eisuke Inoue; Toshihiko Hidaka; Akihiko Okayama
Journal:  PLoS One       Date:  2020-05-27       Impact factor: 3.240

3.  Prevalence of latent tuberculosis in homeless persons: A single-centre cross-sectional study, Germany.

Authors:  Friederike von Streit; Christoph Bartels; Thorsten Kuczius; Christoph Cassier; Joachim Gardemann; Frieder Schaumburg
Journal:  PLoS One       Date:  2019-03-26       Impact factor: 3.240

4.  A novel strategy for interpreting the T-SPOT.TB test results read by an ELISPOT plate imager.

Authors:  Tae Yeul Kim; Ho Eun Chang; Seong-Wook Lee; Soo Hyun Seo; Yun Ji Hong; Jeong Su Park; Kyoung Un Park
Journal:  PLoS One       Date:  2019-09-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.